CN108503584A - A kind of 1,2,3,4- tetrahydroquinolines sulfamide compound and its application - Google Patents
A kind of 1,2,3,4- tetrahydroquinolines sulfamide compound and its application Download PDFInfo
- Publication number
- CN108503584A CN108503584A CN201710106749.8A CN201710106749A CN108503584A CN 108503584 A CN108503584 A CN 108503584A CN 201710106749 A CN201710106749 A CN 201710106749A CN 108503584 A CN108503584 A CN 108503584A
- Authority
- CN
- China
- Prior art keywords
- salt
- compound
- methyl
- disease
- substituent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to pharmaceutical technology fields, it is related to the compound with formula (I) structure feature, wherein R1, R2, X1, X2, Cy1, the definition of m and n is referring to specification, such compound and its pharmaceutically acceptable salt, isomers, pro-drug cocrystallization compound, hydrate, solvate can be used for inhibiting the relevant orphan receptor γ of retinoic acid (ROR γ), and prevent or treat the inflammation that ROR γ are mediated, metabolism, autoimmunity and Other diseases or illness such as psoriasis, rheumatoid arthritis, multiple sclerosis, ulcerative colitis, asthma, lupus erythematosus, oneself immunity hepatitis or I types and type-2 diabetes mellitus, with efficient, low toxicity, the good feature of metabolic stability.
Description
Technical field
The invention belongs to pharmaceutical technology fields, are related to 1,2,3,4- tetrahydroquinoline sulfamide compounds of one kind and its application.
More specifically, can be used as inflammatory syndrome, obstacle or disease of the RORgt conditioning agents for preventing, treating or improving RORgt mediations
Disease.
Background technology
Prior art discloses retinoic acid receptors related orphan receptors(retinoic acid recetor-related
Orphan receptor, ROR)Belong to a member of the transcription factor nuclear receptor superfamily of ligand-dependent.RORgt is the Asias RORs man
One of race's Major Members, are distributed mainly on thymus gland, are expressed in the key cells in immune system.Studies have reported that RORgt promotees
Into T-helper 17(Th17)Cell differentiation simultaneously generates inflammatory cytokine interleukin-17(IL-17)Key regulator, and
Th17 cells and the IL-17 of its secretion play key effect in the occurrence and development of inflammation and autoimmune disease.
2011, the Littman professor seminars of New York University and the Burris professors seminar of Scripps research institutes were same
When delivered that RORgt micromolecular inhibitors are related to be studied on Nature magazines:Littman groups sieve from compound library
Select cardiotonic digoxin(Digoxin)And find its inhibitory activity with RORgt;Burris groups report first non-steroid
Body micromolecular SR1001 can be used as ROR α and RORgt double inhibitors.The same year, professor's Dong class of Anderson Cancer centers
Topic group reports the ursolic acid extracted from natural plants the also activity with selective depression RORgt.2014, Japan
The Sano seminars of dept. of dermatology of Kochi universities are in Japanology Dermatology meeting(SID)Year-end meeting (Annual Meeting of
The Society-for-Investigative-Dermatology) on report a RORgt inhibitor, by take orally to
Medicine can mitigate mouse psoriasiform skin injury.It is before treatment psoriasis has very much that the result of study, which successfully illustrates RORgt,
The target spot of scape.
At the beginning of 2015, by the monoclonal antibody for treating psoriasis by specific inhibition IL-17 of Novartis Co., Ltd's exploitation
Cosentyx(Secukinumab/AIN457)FDA approval listings are obtained, this is first work in treatment psoriasis class pharmaceutical market
For the drug of IL-17, illustrate to influence IL-17 signal paths by ROR γ t inhibitor by treat inflammation and autoimmunity
The Potential feasibility of disease.Currently, IL-17 in terms of anti-inflammatory it has been recognised that.In addition to psoriasis, IL-17 it is a variety of from
It is also played an important role in body immunological diseases, such as rheumatoid arthritis, multiple sclerosis, systemic loupus erythematosus.In addition,
Since chronic inflammation is related in the occurrence and development of tumour, people are also exploring effects of the IL-17 in all kinds of tumours.Such as liver cell
The cell quantity of expression IL-17A and the survival rate of patient infiltrated in cancer specimens is negatively correlated;Patient with breast cancer
Tumor tissues in the Expressions In Lymphocytes IL-17A that infiltrates promote the proliferation etc. of cancer cell, the following IL-17 families control for tumour
Treat good target spot is provided it is highly likely that, therefore, RORgt is considered as anti-inflammatory, antitumor and autoimmune disease
The novel targets of medicament research and development can be used as the inflammation such as cancer, psoriasis, rheumatoid arthritis, multiple sclerosis and autoimmunity
The new way of disease treatment.
Invention content
The purpose of the present invention is the present situations for the prior art, provide a kind of 1,2,3,4- tetrahydroquinoline sulfonamides chemical combination
Object.
Another purpose of the present invention is to provide pharmaceutically may be used for described 1,2,3,4- tetrahydroquinoline sulfamide compounds
Salt, solvate, precursor compound or the polymorph of receiving.
Another purpose of the present invention is to provide the preparation side of described 1,2,3,4- tetrahydroquinoline sulfamide compounds
Method.
Fourth object of the present invention is to provide a kind of pharmaceutical composition.
The 5th purpose of the present invention, provides that described 1,2,3,4- tetrahydroquinoline sulfamide compounds, it pharmaceutically may be used
The salt of receiving, the purposes in medicine preparation of solvate, pro-drug or polymorph.
To achieve the above object, the technical solution adopted by the present invention is that:
A kind of 1,2,3,4- tetrahydroquinoline sulfonic acid amide derivatives, which is characterized in that the derivant structure general formula is:
Wherein:
X1 is C or N;
X2 is halogen, NH or O;
M is optionally from 0,1;
N is optionally from 0,1,2 or 3;
Substituent R 1 is selected from:H, (C1- C3) alkyl, halogen (C1- C3) alkyl, aryl, heteroaryl, heterocycle and naphthenic base;
Substituent R 2 is not present or is located at least one of 2,3,4,5,6 positions, is unsubstituted, mono-substituted, double take
It is generation or polysubstituted, the one kind in following groups of substituent R 2, two or more:Hydrogen, halogen, nitro, hydroxyl, carboxylic
Base, trifluoromethyl, cyano, substituted or unsubstituted amino, phenyl, substituted or unsubstituted (C1-C6) alkyl, substitution do not take
(C1-C6) alkoxy ,-CONH in generation2、-CONHR3、 -CON(R3)2,-COOR3 ,-COR3 ,-NHCOR3 ,-NHCOOR3 bases
Group, wherein R3 is optionally from H, (C1-C6) alkyl, trifluoromethyl, phenyl;When R2 is double or three substitution, substituent group can be identical
Or it is different;
Cy1 be not present or optionally from:H, Ar1, Hetar1 or (C3-C7) naphthenic base;
Above Ar1 indicates to have the monocyclic aromatic hydrocarbon system of 6-10 carbon atom or bicyclic aromatic hydrocarbon system and ring aromatic hydrocarbon and satisfies
And member ring systems, the system is unsubstituted or is replaced by one or more identical or different substituent groups selected from the following:(C1-C6)
Alkyl, (C3-C7) naphthenic base, (C1-C6) alkoxy, carbonyl, carboxyl, amino ,-CONH2、-COOR4、-COR4、-NHCOR4、-
NHCOOR4、-COH(CF3)2、-SONH2,-SOOR4 ,-SOR4 ,-NHSOR4 ,-NHSOOR4 groups substitution;Wherein R4 optionally from H,
(C1-C6) alkyl;
The above Hetar1 indicates saturation 4,5,6,7,8,9 or 10 circle heterocyclic rings with 1,2 or 3 N and/or O and/or S atom, should
Heterocycle is unsubstituted or is replaced by one or more identical or different substituent groups selected from the following:(C1-C6) alkyl, (C3-
C7) naphthenic base, (C1-C6) alkoxy, carbonyl, carboxyl, amino ,-CONH2、-COOR4、-COR4、-NHCOR4、-NHCOOR4、-
COH(CF3)2、-SONH2,-SOOR4 ,-SOR4 ,-NHSOR4 ,-NHSOOR4 groups substitution;Wherein R4 is optionally from H, (C1-C6) alkane
Base.
Preferably, the R1 is selected from methyl.
Preferably, the substituent R 2 is located at least one of 2,3,4,5,6 positions, is unsubstituted, monosubstituted
, it is disubstituted or polysubstituted, one kind in following groups of the substituent group, two or more:Hydrogen, fluorine, chlorine, trifluoro
Methyl, cyano, methyl, phenyl, trifluoromethoxy, tertiary butyl, when R2 is double or three substitution, substituent group can be identical or not
Together.
Preferably, the X1 is optionally from C or N.
Preferably, the X2 is optionally from bromine or N.
Preferably, the Cy1 is optional certainly:1- acetylpiperazinyls, 1- (propiono)-piperazinyl, 1- cyclopropane carbonyl piperazines
Piperazine base, 1- pivaloyl groups piperazinyl, 1- pivaloyl groups piperazinyl, 1- mesylpiperazinyls, 1- piperazine sulfonamide
Base, 1- ethylsulfonyls piperazinyl, morpholinyl, piperazinyl, methyl benzoate base, benzoxy, naphthalene, tetralyl, 3,4- bis-
Hydrogen -1 (2H)-naphthalenone base, piperidyl, 4- piperidine methyl formates base, 4- piperidinecarboxylic acids base, 4- acetamido piperidyls.
It is furthermore preferred that the Cy1 is optionally certainly:1- acetylpiperazinyls, 1- mesylpiperazinyls, 1- ethylsulfonyl piperazines
Base, morpholinyl, methyl benzoate base, 3,4- dihydros -1 (2H)-naphthalenone base, 4- piperidine methyl formates base, benzoxy, 4- piperidines
Formyl, 4- acetamido piperidyls.
Unless otherwise indicated, (C1-C6) alkoxy of the present invention is (C1-C6) straight or branched alkoxyl, refers to
Alkoxy containing 1-6 carbon atom, including but not limited to methoxyl group, ethyoxyl, positive propoxy, isopropoxy, n-butoxy,
Isobutoxy, sec-butoxy, tert-butoxy, amoxy, hexyloxy, oxygroup in heptan or octyloxy.
Unless otherwise indicated, (C1-C6) alkyl of the present invention is (C1-C6) linear or branched alkyl group, refer to containing
The alkyl of 1-6 carbon atom, including but not limited to methyl, ethyl, n-propyl, isopropyl, normal-butyl, isobutyl group, sec-butyl, uncle
Butyl, amyl, hexyl, heptyl or octyl.
Unless otherwise indicated, (C3-C7) naphthenic base of the present invention refers to the naphthenic base containing 3-7 carbon atom, packet
Include but be not limited to cyclopropyl, cyclobutyl, cyclopenta, cyclohexyl, suberyl, ring third and cyclopenta, ring third and cyclohexyl.
Unless otherwise indicated, term halogen is halogen substituent group, including but not limited to fluorine, chlorine, bromine and/or iodine.
Wherein, the term " polysubstituted " in the present invention and " a variety of " refer to three kinds or more, and what is appeared below is also phase
Same meaning.
As best one of embodiment, of the present invention 1,2,3,4- tetrahydroquinoline sulfonic acid amide derivatives are as follows
Particular compound:
- 1 (2H)-Methanesulfomide of 6- (4- Acetylpiperazines)-N- Benzyl-N-methyl -1,2,3,4- tetrahydroquinolines
6- (4- Acetylpiperazines)-N- (the fluoro- benzyls of 2-)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-Methanesulfomide
6- (4- Acetylpiperazines)-N- (the fluoro- benzyls of 4-)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-Methanesulfomide
6- (4- Acetylpiperazines)-N- (the fluoro- benzyls of 3-)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-Methanesulfomide
6- (4- Acetylpiperazines)-N- (4- Methyl-benzvls)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-Methanesulfomide
6- (4- Acetylpiperazines)-N- (2,4- diiluoro-benzyls)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-Methanesulfomide
6- (4- Acetylpiperazines)-N- (the chloro- benzyls of 4-)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-Methanesulfomide
6- (4- Acetylpiperazines)-N- (3- romethyl-benzies)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-methylsulfonyl
Amine
6- (4- Acetylpiperazines)-N- (the chloro- benzyls of 3-)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-Methanesulfomide
6- (4- Acetylpiperazines)-N- (2- romethyl-benzies)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-methylsulfonyl
Amine
6- (4- Acetylpiperazines)-N- (4- trifluoromethvl-Dvrimidins)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-sulfonamide
6- (4- Acetylpiperazines)-N- (the chloro- benzyls of 2-)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-Methanesulfomide
6- (4- Acetylpiperazines)-N- (3- Methyl-benzvls)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-Methanesulfomide
6- (4- Acetylpiperazines)-N- (the fluoro- benzyls of the chloro- 6- of 2-)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-methylsulfonyl
Amine
6- (4- Acetylpiperazines)-N- (4- romethyl-benzies)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-methylsulfonyl
Amine
6- (4- Acetylpiperazines)-N- (2- Methyl-benzvls)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-Methanesulfomide
6- (4- Acetylpiperazines)-N- (4- tert-Butyl-benzyIs)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-Methanesulfomide
6- (4- Acetylpiperazines)-N- (4- phenyl-benzyls)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-Methanesulfomide
6- (4- Acetylpiperazines)-N- phenethyl-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-ethyl sulfonamide
6- (4- Acetylpiperazines)-N- phenylpropyl base-N- methyl-1s, the-the third sulfonamide of 2,3,4- tetrahydroquinolines -1 (2H)
6- (4- Acetylpiperazines)-N- (4- trifluoromethoxies-benzyl)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-methylsulphur
Amide
6- (4- Acetylpiperazines)-N- (4- Cyano-benzyls)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-Methanesulfomide
- 1 (2H)-Methanesulfomide of 6- (4- Nmethanesulphonylpiperazines)-N- Benzyl-N-methyl -1,2,3,4- tetrahydroquinolines
6- (4- Nmethanesulphonylpiperazines)-N- (4- tert-Butyl-benzyIs)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-methylsulfonyl
Amine
6- (4- ethylsulfonyls piperazine)-N- (4- tert-Butyl-benzyIs)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-methylsulfonyl
Amine
6- morpholines-N- (4- tert-Butyl-benzyIs)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-Methanesulfomide
6- (4- amino-benzoic acid methyl esters)-N- (4- tert-Butyl-benzyIs)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-first
Sulfonamide
6- (4- amino-benzoic acids)-N- (4- tert-Butyl-benzyIs)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-methylsulfonyl
Amine
6- (- 1 (2H)-naphthalenone of 4- amino -3,4- dihydros)-N- (4- tert-Butyl-benzyIs)-N- methyl-1s, 2,3,4- tetrahydroquinolines -
1 (2H)-Methanesulfomide
6- (4- piperidine methyl formates)-N- (4- tert-Butyl-benzyIs)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-methylsulfonyl
Amine
6- (4- piperidinecarboxylic acids)-N- (4- tert-Butyl-benzyIs)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-Methanesulfomide
6- (4- piperidine formamides)-N- (4- tert-Butyl-benzyIs)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-Methanesulfomide
6- (4- amino-benzoic acids)-N- (4- tert-Butyl-benzyIs)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-methylsulfonyl
Amine receives salt
6- (4- piperidinecarboxylic acids)-N- (4- tert-Butyl-benzyIs)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-Methanesulfomide sodium
Salt
The bromo- N- of 6- (4- tert-Butyl-benzyIs) -1,2,3,4- tetrahydroquinolines -1 (2H)-Methanesulfomide
The bromo- N- of 6- (4- tert-Butyl-benzyIs) -1,2,3,4- tetrahydroquinolines -1 (2H)-methanesulfonamide hydrochloride
The bromo- N- of 6- (4- tert-Butyl-benzyIs) -1,2,3,4- tetrahydroquinolines -1 (2H)-methanesulfonamide maleat.
To realize above-mentioned second purpose, the technical solution adopted by the present invention is that:
Pharmaceutically acceptable salt, solvate, the precursor chemical combination of the 1,2,3,4- tetrahydroquinoline sulfonic acid amide derivatives
Object or polymorph.
Pharmaceutically acceptable salt, solvate, pro-drug or polymorph, which is characterized in that described pharmaceutically
The salt of receiving is inorganic salts, organic salt or amino-acid salt;
Wherein inorganic salts are:Sodium salt, hydrochloride, trifluoroacetate, sulfate, phosphate, diphosphate, hydrobromate or nitric acid
Salt;
Wherein organic salt is:Maleate, acetate, fumarate, tartrate, succinate, lactate, p-methyl benzenesulfonic acid
Salt, salicylate, oxalates;
Wherein amino-acid salt is:Arginine salt, ornithine salt, lysine salt, leucine salt, isoleucine salt, glycinate, Guang
Propylhomoserin salt, cysteine salt, tyrosine salt, alanine salt, phenylalanine salt, histidine salt, serine salt, threonine salt, egg
Propylhomoserin salt, tryptophan salt, glutamate, aspartate, valine salt, methionine salt, proline salt or hydroxyproline salt.
To realize above-mentioned third purpose, the technical solution adopted by the present invention is that:
Described 1,2,3,4- tetrahydroquinoline sulfonic acid amide derivatives preparation methods, can synthesize to obtain, including such as by following below scheme
Lower step:
Prepare intermediate b
Raw material a and chlorosulphonyl isocyanate and the tert-butyl alcohol are dissolved in dichloromethane, are stirred at room temperature, is condensed up to intermediate b.
Prepare intermediate c
By intermediate b and R1X(X is Cl, Br or I)It is dissolved in n,N-Dimethylformamide, return stirring is to get intermediate c.
Prepare intermediate d
Intermediate c and Cy1 are subjected to coupling reaction or substitution reaction obtains intermediate d.
Prepare intermediate e
Addition trifluoroacetic acid in intermediate d is sloughed to the tertbutyloxycarbonyl of intermediate d.
Prepare compound I
By intermediate d and different halides(Halides f)In being dissolved in n,N-Dimethylformamide, K is added2CO3Stirring, i.e.,
Obtain chemical compounds I.
Halides f:
Wherein, the preparation method of 1,2,3,4- tetrahydroquinoline sulfonic acid amide derivatives pharmaceutically acceptable salts can be according to ability
Prepared by domain conventional method, the compound of the present invention is usually detached as former state, or in the form of its pharmaceutically acceptable salt,
Such as it is reacted and is obtained under normal conditions with inorganic salts, organic salt or amino-acid salt.
To realize above-mentioned 4th purpose, the technical solution adopted by the present invention is that:
A kind of pharmaceutical composition, it includes a)Above-mentioned 1,2,3,4- tetrahydroquinolines sulfonic acid amide derivatives, and/or above-mentioned 1,2,3,
Pharmaceutically acceptable salt, solvate, precursor compound or the polymorph and b of 4- tetrahydroquinoline sulfonic acid amide derivatives)
Its pharmaceutically acceptable carrier.
Described pharmaceutical composition can be the pharmaceutical preparation of solid form or liquid form, the agent of described pharmaceutical composition
Type includes but not limited to tablet, capsule, powder agent, granule, suspension or injection.
To realize above-mentioned 5th purpose, the technical solution adopted by the present invention is that:
Described 1,2,3,4- tetrahydroquinoline sulfonic acid amide derivatives, pharmaceutically acceptable salt, solvate, precursor medicine
The purposes of object, polymorph or pharmaceutical composition in medicine preparation applies in general to inhibit RORgt.Therefore, in some implementations
In example, the present invention provides a kind of relevant orphan receptor γ of inhibition retinoic acid (ROR γ), and prevents or treat ROR γ mediations
Inflammation, metabolism, autoimmunity and Other diseases or illness, it includes administering provide compound or composition.More precisely
It says, compounds and compositions described herein serve as the conditioning agent of ROR γ.
The disease and the patient's condition that can be treated according to the method for the present invention include but is not limited to inflammation, the generation that ROR γ are mediated
Thank, autoimmunity and Other diseases or illness, as psoriasis, rheumatoid arthritis, multiple sclerosis, ulcerative colitis,
Asthma, lupus erythematosus, oneself immunity hepatitis or I types and II types glycosuria, diabetic complication, nephrosis, diabetes
Property retinopathy, diabetic retinitis, diabetic microangiopathy, ophthalmology disease, uveitis, atherosclerosis,
Psoriasis arthropathica, atopic dermatitis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, ephritis, organ are of the same race
Allograft rejection, fibroid lung, cystic fibrosis, renal insufficiency, pulmonary tuberculosis, Chronic Obstructive Pulmonary Disease, meat sample
It is inflammation, allergic rhinitis, allergic conjunctivitis after tumor disease, invasive staphyloderma, cataract operation, chronic
Nettle rash, systemic loupus erythematosus, asthma, allergic asthma, steroid resistant asthma, neutrophilic asthma, periodontal
Disease, periodontitis, gingivitis, gum disease, diastolic cardiomyopathies, myocardial infarction, myocarditis, chronic heart failure, blood vessel are narrow
Narrow, restenosis, Reperfu- sion obstacle, glomerulonephritis, solid tumor and cancer, chronic lymphocytic leukemia, chronic granulocyte
Property leukaemia, Huppert's disease, pernicious myeloma, Hodgkin's disease and carcinoma of urinary bladder, breast cancer, cervix cancer, colon cancer,
Lung cancer, prostate cancer or gastric cancer.
Further, the present invention also provides described 1,2,3,4- tetrahydroquinoline sulfonic acid amide derivatives or its pharmacy to connect
Application of salt, solvate, precursor compound or the polymorph received in the drug for preparing treatment inflammation disease.
Further, the present invention also provides described 1,2,3,4- tetrahydroquinoline sulfonic acid amide derivatives or its pharmacy to connect
Application of salt, solvate, precursor compound or the polymorph received in the drug for preparing treatment autoimmune disease.
Further, the present invention also provides described 1,2,3,4- tetrahydroquinoline sulfonic acid amide derivatives or its pharmacy to connect
Application of salt, solvate, precursor compound or the polymorph received in the drug for preparing treatment metabolism related diseases.
Further, the present invention also provides described 1,2,3,4- tetrahydroquinoline sulfonic acid amide derivatives or its pharmacy to connect
Application of salt, solvate, precursor compound or the polymorph received in the drug for preparing treating cancer disease.
Best, the present invention also provides described 1,2,3,4- tetrahydroquinoline sulfonic acid amide derivatives or its is pharmaceutically acceptable
Salt, solvate, precursor compound or polymorph preparing psoriasis, the rheumatoid joint that treatment is mediated by ROR γ
Inflammation, multiple sclerosis, ulcerative colitis, asthma, lupus erythematosus, oneself immunity hepatitis or I types and type-2 diabetes mellitus, Crow
Engler's disease, breast cancer, lung cancer, colon cancer drug in application.
Specific implementation mode
The present invention is explained further below in conjunction with specific embodiment, but embodiment does not do any type of limit to the present invention
It is fixed.In the following examples, the experimental methods for specific conditions are not specified, usually according to normal condition, or suggest according to manufacturer
Condition.
In chemicals of the present invention, when any variable (such as R1, R2 etc.) occurs more than once in any component,
Then its definition occurred every time is independently of other definition occurred every time.Equally, allow the combination of substituent group and variable, as long as this
Kind combination makes compound stablize.Indicate that signified key may be connected to any ring original that can replace from the line of substituent group cut-in loop system
On son.If loop system is polycyclic, it means that this key is connected only on any carbon atom appropriate of adjacent loops.It is appreciated that
Those of ordinary skill in the art may be selected the compounds of this invention substituent group and substitution pattern and provide chemically stable and can
The compound being readily synthesized from readily available raw material by art technology and the method for following proposition.If substituent group
Itself it is exceeded a group substitution, it should be understood that these groups can be in identical carbon atoms or on different carbon atoms, as long as making knot
Structure is stablized.Phrase " being optionally substituted by one or more substituents " is considered and phrase " optionally being replaced by least one substituent group "
Quite and preferred embodiment will have 0-3 substituent group in the case.
Terms used herein " alkyl " and " alkylidene " mean include have particular carbon atom number branch and straight chain
Saturated fat alkyl.For example, in " C1-C6 alkyl " definition of " C1-C6 " include with linear chain or branched chain arrange have 1,2,
3, the group of 4,5 or 6 carbon atoms.For example, " C1-6 alkyl " specifically includes methyl, ethyl, n-propyl, isopropyl, positive fourth
Base, tertiary butyl, isobutyl group, amyl, sec-butyl, tertiary butyl, hexyl.Term " naphthenic base " refers to the list with particular carbon atom number
Ring filling aliphatic group.Such as " naphthenic base " includes cyclopropyl, methyl-cyclopropyl, 2,2- dimethyl-cyclobutyls, 2- ethyls-ring
Amyl, cyclohexyl etc..
Terms used herein " heteroaryl " represents in ring up to 6 in the monocycle of the stabilization of up to 6 atoms or each ring
A atom bicyclic carbocyclic, wherein at least one ring are aromatic rings and the hetero atom selected from O, N and S containing 1-4.This definition
Heteroaryl in range includes but not limited to:Imidazole radicals, triazolyl, pyrazolyl, base, the thienyl, oxazolyl, isoxazoles of muttering of barking
Base, pyrazinyl, pyridazinyl, pyridyl group, pyrimidine radicals, pyrrole radicals.Definition for following heteroaryl, " heteroaryl " also are understood as wrapping
Include the N- oxide derivatives of any heteroaryl containing nitrogen.In heteroaryl substituent be bicyclic and ring is non-containing there are one
Armaticity does not contain in heteroatomic example, it should be understood that respectively through aromatic rings or through being connected containing heteroatomic ring.
Term " heterocycle " used herein or " heterocycle " refer to containing 1-4 be selected from O, N and S heteroatomic 5 yuan
Or 6 yuan of armaticity or non-aromatic heterocyclic rings, and include bicyclic radicals." heterocycle " therefore include above mentioned heteroaryl,
Including its dihydro and tetrahydro analog." heterocycle " further example includes but not limited to:It is imidazole radicals, indazolyl, different
Thiazolyl, isoxazolyl, oxadiazolyl, oxazolyls, oxetanyl, pyranose, pyrazinyl, pyrazolyl, pyridazinyl, pyridine
Base, pyrimidine radicals, pyrrole radicals, quinoxalinyls, tetrazole radical, thiadiazolyl group, thiazolyl, thienyl, triazolyl, l, 4- alkyl dioxins,
Pyrrolidinyl, glyoxalidine base, dihydro-isoxazole base, dihydro isothiazolyl, Er Qing oxadiazolyls, dihydro-oxazole base, dihydro pyrrole
Piperazine base, pyrazoline base, dihydropyridine base, dihydro-pyrimidin base, pyrrolin base, dihydro tetrazole radical, thiodiazoline base, dihydro
Thiazolyl, dihydrothiophene, dihydro triazolyl, dihydro azetidinyl, tetrahydrofuran base and tetrahydro-thienyl and its N- oxygen
Compound.The connection of heterocyclic substituent can be realized by carbon atom or by hetero atom.
As will be appreciated by a person skilled in the art, " halogen " used herein means to include chlorine, fluorine, bromine and iodine.
Unless otherwise defined, alkyl, naphthenic base, aryl, heteroaryl and heterocyclyl substituent can be considered it is unsubstituted or
Substitution.For example, (C1-C4) alkyl can be selected from OH, halogen, alkoxy, dialkyl amido or miscellaneous by one, two or three
The substituent group of ring group, such as morpholinyl, piperidyl etc. replaces.
The present invention includes the free form of type I compound, also includes its pharmaceutically acceptable salt and stereoisomer.This
The specific exemplary compounds of some in text are the protonated salt of aminated compounds.Term " free form " refers to non-salt shape
The aminated compounds of formula.The pharmaceutically acceptable salt being included includes not only the exemplary of specific compound described herein
Salt also includes the typical pharmaceutically acceptable salt of all type I compound free forms.Techniques known in the art point can be used
Free form from the compound specific salts.For example, can by with alkali dilute aqueous solution appropriate such as NaOH dilute aqueous solutions,
Potassium carbonate dilute aqueous solution, weak aqua ammonia and sodium bicarbonate dilute aqueous solution, which handle the salt, makes free form regenerate.Free form is certain
Physical property for example in polar solvent respectively more or less distinguish solubility with its by salifie form, but for invention purpose this
Respectively free form is suitable with its in terms of other pharmacy for kind hydrochlorate and alkali salt.
It can synthesize the present invention's from the compounds of this invention of alkaline part or acidic moiety is contained by conventional chemical processes
Pharmaceutically acceptable salt.In general, by ion-exchange chromatography or passing through free alkali and stoichiometric amount or excessive required salt
The reaction in the combination of appropriate solvent or multi-solvents of the inorganic or organic acid of form prepares the salt of alkali compounds.Similar,
The salt of acid compound is formed by being reacted with appropriate inorganic or organic base.
Therefore, the pharmaceutically acceptable salt of the compounds of this invention includes by alkaline the compounds of this invention and inorganic or have
Machine acid reacts the conventional non-toxic salts for the compounds of this invention to be formed.For example, conventional nontoxic salts include deriving from inorganic acid such as salt
The salt of acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid etc. also includes from organic acid such as acetic acid, propionic acid, succinic acid, second
Alkyd, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, flutter acid, maleic acid, hydroxymaleic acid, phenylacetic acid,
Glutamic acid, benzoic acid, salicylic acid, p-aminobenzene sulfonic acid, 2- acetoxyl groups-benzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid,
The salt of the preparations such as ethane disulfonic acid, oxalic acid, isethionic acid, trifluoroacetic acid.
If the compounds of this invention is acid, " pharmaceutically acceptable salt " appropriate refers to by pharmaceutically acceptable
Nontoxic alkali include salt prepared by inorganic base and organic base.Salt derived from inorganic base includes aluminium salt, ammonium salt, calcium salt, mantoquita, iron
Salt, ferrous salt, lithium salts, magnesium salts, manganese salt, manganous salt, sylvite, sodium salt, zinc salt etc..Particularly preferred ammonium salt, calcium salt, magnesium salts, sylvite
And sodium salt.Salt derived from pharmaceutically acceptable organic nontoxic alkali, the alkali include the salt of primary amine, secondary amine and tertiary amine, substitution
Amine include naturally occurring substitution amine, cyclic amine and deacidite such as arginine, glycine betaine, caffeine, courage
Alkali, N, N'- dibenzyl-ethylenediamins, diethylamine, 2- DEAE diethylaminoethanols, 2- dimethylaminoethanols, ethylaminoethanol, second
Hydramine, ethylenediamine, N- ethyl morpholines, N- ethyl piperidines, gucosamine, Glucosamine, histidine, hydroxycobalamin, isopropyl
Amine, lysine, methyl glucose osamine, morpholine, piperazine, piperidines, croak smack one's lips, polyamines resin, procaine, purine, theobromine, three
Ethamine, trimethylamine, tripropyl amine (TPA), tromethamine etc..
Since the acidic moiety such as carboxyl of deprotonation in compound in physiological conditions can be anion, and it is this
The charge carried then can be by the internal protonated or alkylated alkaline part such as quaternary nitrogen atom with cation
Balance is offset, it is noted that the compounds of this invention is potential inner salt or amphoteric ion.
Composition of the present invention can be liquid, semiliquid or solid form, according to being suitable for administration way used
The mode of diameter is prepared.Composition of the present invention can be administered according to following administering mode:In oral, parenteral, peritonaeum, it is quiet
The modes such as arteries and veins is interior, transdermal, sublingual, intramuscular, rectum, oral cavity, intranasal, liposome.
Orally administered composition can be solid, gel or liquid.The example of solid pharmaceutical preparation includes but not limited to tablet, capsule
Agent, granule and bulk powder.These preparations can selectively contain adhesive, diluent, disintegrant, lubricant, glidant,
Sweetener and corrigent etc..The example of adhesive includes but not limited to microcrystalline cellulose, glucose solution, mucialga of arabic gummy, bright
Sol solution, sucrose and gelatinized corn starch;The example of lubricant includes but not limited to talcum, starch, magnesium stearate, calcium stearate, tristearin
Acid;The example of diluent includes but not limited to lactose, sucrose, starch, mannitol, Dicalcium Phosphate;The example of glidant includes
But it is not limited to silica;The example of disintegrant includes but not limited to croscarmellose sodium, primojel, algae
Acid, cornstarch, potato starch, methylcellulose, agar and carboxymethyl cellulose.
The present composition is given with parenteral, generally based on injection, including subcutaneous, intramuscular or intravenous injection.Note
Any conventionally form can be made by penetrating agent, and such as liquid solution or suspension is suitable for being dissolved or suspended in liquid before injection
In solid form or emulsion.The example that can be used for the carrier of the pharmaceutical acceptable of injection of the present invention includes but not limited to
Aqueous carrier, non-aqueous carrier, antimicrobial, isotonic agent, buffer, antioxidant, suspension and dispersant, emulsifier, chelating
Agent and other pharmaceutically acceptable substances.The example of aqueous carrier includes sodium chloride injection, woods format injection, isotonic Portugal
Grape sugar injection, Sterile Water Injection, glucose and Lactated ringer's injection;The example of non-aqueous carrier includes that plant comes
Fixing oil, cottonseed oil, corn oil, sesame oil and the peanut oil in source;The example of antimicrobial includes metacresol, benzylalcohol, neoprene
Alcohol, benzalkonium chloride etc.;The example of isotonic agent includes sodium chloride and glucose;Buffer includes phosphate and citrate.
The present composition can also be prepared into sterile freeze drying powder injection, and compound is dissolved in buffer solution of sodium phosphate,
Wherein containing glucose or other suitable excipient, then under standard conditions well known by persons skilled in the art by solution without
Bacterium is filtered, and is followed by freeze-drying, is obtained required preparation.
Except known in the literature or in addition to the standard method of illustration, can be used as shown in following scheme in experimental arrangement
Reaction prepare the compounds of this invention.Therefore, following illustrative approach is purpose to illustrate without being limited to listed chemical combination
Object or any specific substituent group.The substituent group number shown in scheme not necessarily meets number used in claim,
And for clarity, showing monosubstituted base to be connected under the hereinbefore definition of Formulas I allows to have in the compound of multi-substituent.
The present invention will be further described for following embodiment, but the embodiment is not intended to limit the protection model of the present invention
It encloses.
- 1 (2H)-methylsulphur of 1 6- of embodiment (4- Acetylpiperazines)-N- Benzyl-N-methyl -1,2,3,4- tetrahydroquinolines
Amide(Compound 1)Preparation
Step 1:Prepare tertiary butyl ((the bromo- 3,4- dihydroquinoline -1 (2H) of 6-) sulfonyl) carbamate(Intermediate (b))
Chlorosulfonic acid isocyanate (0.75g, 5mmol), the tert-butyl alcohol (0.37g, 5mmol) are dissolved in dichloromethane (15ml), and ice bath stirs
Mix 0.5hr.Be added again into reaction solution the bromo- 1,2,3,4- tetrahydroquinolines (1.05g, 5mmol) of 6- and triethylamine (1.5g,
15mmol), 6hr is stirred at room temperature.To the end of reaction, add 15ml water, extracted with dichloromethane (10ml × 3), merges organic phase,
Anhydrous sodium sulfate is dried, and concentration, column chromatography for separation (PE are evaporated under reduced pressure after filtering: EtOAc = 20:1) white solid, is obtained
1.3g, yield 67%.Obtain intermediate (b);
Step 2:Prepare N- tert-butyl-n -s methyl-((the bromo- 3,4- dihydroquinoline -1 (2H) of 6-) sulfonyl) carbamate(In
Mesosome (c))
By intermediate (b) (0.76g, 1.84mmol)With potassium carbonate (0.51g, 3.7mmol)It is dissolved in DMF (15ml), iodine first is added dropwise
Alkane (0.18mL, 2.8mmol), 110 DEG C of reflux.TLC detection reactions.It lets cool after reaction, adds 35ml water, use ethyl acetate
(30ml × 3) extract, and merge organic phase, and anhydrous sodium sulfate drying is evaporated under reduced pressure concentration, column chromatography for separation (PE after filtering:
EtOAc = 20:1) faint yellow solid 0.522g, yield 66%, are obtained.Obtain intermediate (c);
Step 3:Prepare 6- (4- Acetylpiperazines)-N- tertbutyloxycarbonyl-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-first
Sulfonamide(Intermediate (d))
Intermediate (c) (1.82g, 4.8mmol), palladium (52mg, 0.24mmol), 2- dicyclohexyl phosphines -2 ', 6 '-dimethoxies
Base biphenyl (240mg, 0.48mmol), cesium carbonate (2.32g, 7.2mmol) are dissolved in dioxane (15ml), add 1- acetyl piperazines
Piperazine (0.92g, 7.2mmol), nitrogen protection, 100 DEG C of return stirring 6hr, reaction solution are in brown clear liquid.Wait for that reaction solution is down to room
15ml water is added in temperature, is extracted with ethyl acetate (10ml × 3), merges organic phase, and anhydrous sodium sulfate drying is depressurized after filtering and steamed
Evaporate concentration, column chromatography for separation (PE:EtOAc = 1:1) white solid 1.5g, yield 75%, are obtained.Intermediate (d) is obtained,1H
NMR (400 MHz, dmso): δ 7.20 (d, J = 9.0 Hz, 1H), 6.81 (dd, J = 9.0, 2.7 Hz,
1H), 6.76 (s, 1H), 3.76 – 3.64 (m, 2H), 3.55 (s, 4H), 3.16 (s, 3H), 3.14 –
2.96 (m, 4H), 2.71 (t, J = 6.5 Hz, 2H), 2.03 (s, 5H), 1.94 – 1.79 (m, 2H),
1.26 (s, 9H);
Step 4:Prepare 6- (4- Acetylpiperazines)-N- methyl-1s, 2,3,4- tetrahydroquinolines -1 (2H)-Methanesulfomide(It is intermediate
Body (e))
Intermediate (d) (1.5g, 3.3mmol) is dissolved in dichloromethane, and trifluoroacetic acid (3mL, 33mmol) is added, is stirred at room temperature
2hr is slowly added into reaction solution in trash ice (40g), and saturated solution of sodium bicarbonate, stirring, until PH=8, use ethyl acetate is added dropwise
(30ml×3)Extraction, merges organic phase, and anhydrous sodium sulfate drying is evaporated under reduced pressure concentration, column chromatography for separation (PE after filtering:
EtOAc = 1:2) yellow solid 0.7g, yield 60%, are obtained.Intermediate (e) is obtained,1H NMR (400 MHz, CDCl3 ) δ
7.44 (d, J = 9.0 Hz, 1H), 6.86 – 6.52 (m, 2H), 4.37 (s, 1H), 3.68 (dd, J =
16.8, 11.1 Hz, 4H), 3.57 (s, 2H), 3.14 – 2.94 (m, 4H), 2.76 (t, J = 6.7 Hz,
2H), 2.59 (d, J = 5.4 Hz, 3H), 2.08 (s, 3H), 1.98 (p, J = 6.7 Hz, 3H);
Step 5:Prepare -1 (2H)-Methanesulfomide of 6- (4- Acetylpiperazines)-N- Benzyl-N-methyl -1,2,3,4- tetrahydroquinolines
Intermediate (e) (0.1g, 0.28mmol) and potassium carbonate (0.07g, 0.56mmol) are dissolved in DMF (5ml), benzyl bromine is added dropwise
(0.145mg, 0.85mmol) is stirred at room temperature.TLC detection reactions.It lets cool after reaction, adds 15ml water, use ethyl acetate
(10ml × 3) extract, and merge organic phase, and anhydrous sodium sulfate drying is evaporated under reduced pressure concentration, column chromatography for separation (PE after filtering:
EtOAc = 1:1) white solid 0.070g, yield 56%, are obtained.Obtain compound 1.
Embodiment 2- 22
Embodiment 1 is repeated, difference is:Using different raw materials, to which compound 2-22 be made.It is specific as follows:
By 2- fluorine bromobenzyl, 4- fluorine bromobenzyl, 3- fluorine bromobenzyl, 4- methyl bromobenzyl, 2,4- difluorobenzyl bromides, 4- chlorine bromobenzyl, 3- trifluoromethyls
Bromobenzyl, 3- chlorine bromobenzyl, 2- trifluoromethyls bromobenzyl, the chloro- 4- trifluoromethyl pyrimidines of 2-, 2- chlorine bromobenzyl, 3- methyl bromobenzyl, the chloro- 6- of 2-
Fluoro benzyl bromide, 4- trifluoromethyls bromobenzyl, 2- methyl bromobenzyl, 4- tertiary butyls bromobenzyl, 4- phenyl bromobenzyl, (2- bromoethyls) benzene, 1- are bromo-
3- phenyl-propanes, 4- trifluoromethoxies bromobenzyl, 4- cyano-benzyl bromides respectively with the intermediate (e) and potassium carbonate system in above-described embodiment
It is standby to form, compound 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22 is corresponded to respectively.
- 1 (2H)-methylsulphur of 23 6- of embodiment (4- Nmethanesulphonylpiperazines)-N- Benzyl-N-methyl -1,2,3,4- tetrahydroquinolines
The preparation of amide
Embodiment 1 is repeated, difference is:Using different raw materials, to which compound 23 be made.It is specific as follows:
By 1- Nmethanesulphonylpiperazines and intermediate (c) in palladium, 2- dicyclohexyl phosphines -2 ', 6 '-dimethoxy-biphenyls, carbonic acid
It is coupled under the catalysis of caesium, then takes off Boc, add bromobenzyl, finally obtained compound 23.
Embodiment 24-32
Embodiment 1 is repeated, difference is:Using different raw materials, to which compound 24-32 be made.It is specific as follows:
By 1- Nmethanesulphonylpiperazines, 1- ethylsulfonyls piperazine, morpholine, 4-aminobenzoic acid methyl esters, 6- amino -3,4- dihydros -1
(2H)-naphthalenone, 4- piperidine methyl formates, N- piperidines -4- methyl acetamides and intermediate (c) are in palladium, 2- dicyclohexyls
Phosphine -2 ', 6 '-dimethoxy-biphenyls, cesium carbonate catalysis under be coupled, then take off Boc, add 4- tertiary butyl bromobenzyls, point
It Zhi get not compound 24,25,26,27,29,30,32.
By compound 27,30 in the methanol/water solution of sodium hydroxide back hydrolysis, respectively be made compound 33,34, add
Acid neutralizes, and extraction obtains compound 28,31 respectively.
Embodiment 35-37
Embodiment 1 is repeated, difference is:Without the coupling of step 2 to methylate with step 3, compound 35 is obtained.Use salt
Its salt, i.e. compound 36,37 is made in acid, maleic acid respectively.
The chemical constitution for the target product that the present invention has synthesized is shown in Table 1.Nucleus magnetic hydrogen spectrum, mass spectrometer system characterize target product
Chemical constitution, shown in tables of data 2.
The chemical constitution of 1. target product of table
Compound | R1 | R2 | m | n | X1 | X2 | Cy1 |
1 | -CH3 | H | 0 | 1 | C | 1- Acetylpiperazines | |
2 | -CH3 | 2-F | 0 | 1 | C | 1- Acetylpiperazines | |
3 | -CH3 | 4-F | 0 | 1 | C | 1- Acetylpiperazines | |
4 | -CH3 | 3-F | 0 | 1 | C | 1- Acetylpiperazines | |
5 | -CH3 | 4-CH3 | 0 | 1 | C | 1- Acetylpiperazines | |
6 | -CH3 | 2,4-F | 0 | 1 | C | 1- Acetylpiperazines | |
7 | -CH3 | 4-Cl | 0 | 1 | C | 1- Acetylpiperazines | |
8 | -CH3 | 3-CF3 | 0 | 1 | C | 1- Acetylpiperazines | |
9 | -CH3 | 3-Cl | 0 | 1 | C | 1- Acetylpiperazines | |
10 | -CH3 | 2-CF3 | 0 | 1 | C | 1- Acetylpiperazines | |
11 | H | 3-CF3 | 0 | 0 | N | 1- Acetylpiperazines | |
12 | -CH3 | 2-Cl | 0 | 1 | C | 1- Acetylpiperazines | |
13 | -CH3 | 3-CH3 | 0 | 1 | C | 1- Acetylpiperazines | |
14 | -CH3 | 2-Cl-6-F | 0 | 1 | C | 1- Acetylpiperazines | |
15 | -CH3 | 4-CF3 | 0 | 1 | C | 1- Acetylpiperazines | |
16 | -CH3 | 2-CH3 | 0 | 1 | C | 1- Acetylpiperazines | |
17 | -CH3 | 4-C(CH3)3 | 0 | 1 | C | 1- Acetylpiperazines | |
18 | -CH3 | 4-Ph | 0 | 1 | C | 1- Acetylpiperazines | |
19 | -CH3 | H | 0 | 2 | C | 1- Acetylpiperazines | |
20 | -CH3 | H | 0 | 3 | C | 1- Acetylpiperazines | |
21 | -CH3 | 4-OCF3 | 0 | 1 | C | 1- Acetylpiperazines | |
22 | -CH3 | 4-CN | 0 | 1 | C | 1- Acetylpiperazines | |
23 | -CH3 | H | 0 | 1 | C | 1- Nmethanesulphonylpiperazines | |
24 | -CH3 | 4-C(CH3)3 | 0 | 1 | C | 1- Nmethanesulphonylpiperazines | |
25 | -CH3 | 4-C(CH3)3 | 0 | 1 | C | 1- ethylsulfonyl piperazines | |
26 | -CH3 | 4-C(CH3)3 | 0 | 1 | C | Morpholine | |
27 | -CH3 | 4-C(CH3)3 | 1 | 1 | C | NH | 4 benzoic acid methyl esters |
28 | -CH3 | 4-C(CH3)3 | 1 | 1 | C | NH | 4 benzoic acid |
29 | -CH3 | 4-C(CH3)3 | 1 | 1 | C | NH | 3,4- dihydros -1 (2H)-naphthalenone |
30 | -CH3 | 4-C(CH3)3 | 0 | 1 | C | 4- piperidine methyl formates, | |
31 | -CH3 | 4-C(CH3)3 | 0 | 1 | C | 4- piperidinecarboxylic acids | |
32 | -CH3 | 4-C(CH3)3 | 0 | 1 | C | N- piperidines -4- methyl acetamides | |
33 | -CH3 | 4-C(CH3)3 | 1 | 1 | C | NH | 4 benzoic acid |
34 | -CH3 | 4-C(CH3)3 | 0 | 1 | C | 4- piperidinecarboxylic acids | |
35 | H | 4-C(CH3)3 | 1 | 1 | C | Br | |
36 | H | 4-C(CH3)3 | 1 | 1 | C | Br | |
37 | H | 4-C(CH3)3 | 1 | 1 | C | Br |
The nucleus magnetic hydrogen spectrum of 2. target compound of table, mass spectrometric data
Compound | 1H NMR(400 MHz,DMSO-d6) | MS(m/z) |
1 | 7.32 (ddd, J = 20.4, 13.9, 7.9 Hz, 6H), 6.81 (d, J = 8.9 Hz, 1H), 6.74 (s, 1H), 4.29 (s, 2H), 3.65 – 3.59 (m, 6H), 3.55 (s, 4H), 3.13 – 3.01 (m, 4H), 2.76 (t, J = 6.6 Hz, 3H), 2.60 (s, 4H), 2.04 (s, 6H), 1.99 – 1.89 (m, 2H). | 443.0[M+H]+ |
2 | 7.45 – 7.28 (m, 3H), 7.22 (dd, J = 13.0, 6.7 Hz, 2H), 6.79 (d, J = 9.1 Hz, 1H), 6.73 (s, 1H), 4.38 (s, 2H), 3.58 (t, J = 9.3 Hz, 6H), 3.10 (d, J = 4.3 Hz, 2H), 3.06 – 2.96 (m, 2H), 2.76 (t, J = 6.7 Hz, 2H), 2.66 (s, 3H), 2.04 (s, 3H), 1.94 (dd, J = 12.0, 6.1 Hz, 2H) | 461.0[M+H]+ |
3 | 7.36 – 7.25 (m, 3H), 7.17 (t, J = 8.7 Hz, 2H), 6.79 (d, J = 9.1 Hz, 1H), 6.75 – 6.68 (m, 1H), 4.27 (s, 2H), 3.58 (dd, J = 14.8, 8.5 Hz, 7H), 3.09 (s, 2H), 3.03 (s, 2H), 2.75 (t, J = 6.5 Hz, 3H), 2.59 (s, 3H), 2.03 (s, 3H), 1.97 – 1.78 (m, 2H) | 461.0[M+H]+ |
4 | 7.37 (dd, J = 14.7, 7.2 Hz, 1H), 7.31 (d, J = 9.0 Hz, 1H), 7.11 (t, J = 6.7 Hz, 2H), 7.02 (d, J = 10.0 Hz, 1H), 6.78 (d, J = 9.0 Hz, 1H), 6.71 (s, 1H), 4.30 (s, 2H), 3.58 (d, J = 5.0 Hz, 2H), 3.53 (s, 4H), 3.08 (s, 2H), 3.01 (s, 2H), 2.73 (t, J = 5.8 Hz, 2H), 2.61 (s, 3H), 2.01 (s, 3H), 1.97 – 1.79 (m, 2H) | 461.0[M+H]+ |
5 | 7.31 (d, J = 9.0 Hz, 1H), 7.13 (s, 4H), 6.78 (d, J = 9.1 Hz, 1H), 6.71 (s, 1H), 4.21 (s, 2H), 3.64 – 3.45 (m, 6H), 3.11 – 3.04 (m, 2H), 3.04 – 2.96 (m, 2H), 2.74 (t, J = 6.6 Hz, 2H), 2.55 (s, 3H), 2.26 (s, 3H), 2.01 (s, 3H), 1.95 – 1.80 (m, 2H) | 457.0[M+H]+ |
6 | 7.38 (dd, J = 15.7, 8.2 Hz, 1H), 7.25 (dd, J = 17.9, 9.4 Hz, 2H), 7.08 (t, J = 8.3 Hz, 1H), 6.75 (d, J = 9.1 Hz, 1H), 6.70 (s, 1H), 4.32 (s, 2H), 3.54 (s, 7H), 3.07 (s, 2H), 3.01 (s, 2H), 2.73 (t, J = 6.5 Hz, 2H), 2.62 (s, 3H), 2.01 (s, 3H), 1.94 – 1.74 (m, 2H) | 479.0[M+H]+ |
7 | 7.38 (d, J = 8.2 Hz, 2H), 7.28 (t, J = 8.1 Hz, 3H), 6.77 (d, J = 9.0 Hz, 1H), 6.71 (s, 1H), 4.26 (s, 2H), 3.59 – 3.51 (m, 6H), 3.07 (s, 2H), 3.01 (s, 2H), 2.73 (t, J = 6.6 Hz, 2H), 2.58 (s, 3H), 2.01 (s, 3H), 1.96 – 1.79 (m, 2H) | 477.0[M+H]+ |
8 | 7.67 (d, J = 5.1 Hz, 1H), 7.62 (s, 1H), 7.59 (d, J = 6.0 Hz, 2H), 7.33 (d, J = 9.0 Hz, 1H), 6.79 (d, J = 9.1 Hz, 1H), 6.74 (s, 1H), 4.41 (s, 2H), 3.68 – 3.60 (m, 2H), 3.56 (d, J = 4.0 Hz, 4H), 3.14 – 3.07 (m, 2H), 3.07 – 2.97 (m, 2H), 2.76 (t, J = 6.6 Hz, 2H), 2.64 (s, 3H), 2.04 (s, 3H), 1.99 – 1.87 (m, 2H) | 511.0[M+H]+ |
9 | 7.43 – 7.17 (m, 5H), 6.78 (dd, J = 9.1, 2.5 Hz, 2H), 6.72 (s, 0H), 4.28 (s, 1H), 3.64 – 3.56 (m, 6H), 3.53 (d, J = 4.7 Hz, 2H), 3.14 – 3.04 (m, 4H), 3.04 – 2.97 (m, 1H), 2.73 (t, J = 6.7 Hz, 1H), 2.60 (s, 2H), 2.01 (s, 1H), 1.92 (dd, J = 12.0, 6.1 Hz, 2H) | 477.0[M+H]+ |
10 | 7.78 – 7.61 (m, 2H), 7.58 – 7.44 (m, 2H), 7.30 (d, J = 9.0 Hz, 1H), 6.79 (d, J = 9.0 Hz, 1H), 6.72 (s, 1H), 4.47 (s, 2H), 3.63 – 3.57 (m, 2H), 3.53 (s, 4H), 3.08 (s, 2H), 3.02 (s, 2H), 2.73 (t, J = 6.5 Hz, 6H), 2.68 (s, 3H), 2.48 (s, 2H), 2.01 (s, 6H), 1.97 – 1.88 (m, 2H) | 510.9[M+H]+ |
11 | 9.00 (d, J = 4.9 Hz, 1H), 7.64 (d, J = 5.0 Hz, 1H), 7.20 (d, J = 9.0 Hz, 1H), 6.79 (dd, J = 9.0, 2.5 Hz, 1H), 6.70 (d, J = 2.0 Hz, 1H), 3.98 – 3.87 (m, 2H), 3.57 (s, 13H), 3.53 (s, 4H), 3.13 – 3.03 (m, 4H), 3.02 – 2.91 (m, 2H), 2.62 (t, J = 6.3 Hz, 2H), 2.02 (s, 5H), 1.96 – 1.82 (m, 2H) | 499.0[M+H]+ |
12 | 7.49 – 7.41 (m, 1H), 7.41 – 7.26 (m, 4H), 6.78 (dd, J = 9.1, 2.4 Hz, 1H), 6.71 (d, J = 2.2 Hz, 1H), 4.40 (s, 2H), 3.64 – 3.56 (m, 7H), 3.53 (d, J = 4.8 Hz, 4H), 3.12 – 3.05 (m, 4H), 3.03 – 2.95 (m, 2H), 2.73 (t, J = 6.7 Hz, 5H), 2.66 (s, 3H), 2.01 (s, 3H), 1.98 – 1.78 (m, 2H) | 477.0[M+H]+ |
13 | 7.32 (d, J = 9.0 Hz, 1H), 7.20 (t, J = 7.5 Hz, 1H), 7.14 – 6.95 (m, 2H), 6.78 (d, J = 9.2 Hz, 1H), 6.72 (s, 1H), 4.21 (s, 2H), 3.69 – 3.56 (m, 2H), 3.53 (s, 4H), 3.08 (s, 2H), 3.01 (s, 2H), 2.73 (t, J = 6.5 Hz, 2H), 2.57 (s, 3H), 2.24 (s, 3H), 2.01 (s, 3H), 1.96 – 1.79 (m, 2H) | 457.0[M+H]+ |
14 | 7.43 (dd, J = 14.3, 8.1 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H), 7.33 – 7.20 (m, 2H), 6.81 – 6.71 (m, 1H), 6.69 (s, 1H), 4.43 (s, 2H), 3.60 – 3.51 (m, 7H), 3.07 (d, J = 4.7 Hz, 2H), 3.03–2.92 (m, 2H), 2.73 (t, J = 6.6 Hz, 2H), 2.53 (s, 3H), 2.01 (s, 3H), 1.96 – 1.81 (m, 2H) | 494.9[M+H]+ |
15 | 7.70 (s, 2H), 7.48 (d, J = 6.3 Hz, 2H), 7.30 (d, J = 9.0 Hz, 1H), 6.78 (d, J = 8.1 Hz, 1H), 6.71 (s, 1H), 4.39 (s, 2H), 3.59 (s, 4H), 3.53 (s, 6H), 3.08 (s, 4H), 3.02 (s, 2H), 2.74 (s, 2H), 2.63 (s, 3H), 2.01 (s, 3H), 1.92 (s, 2H) | 511.0[M+H]+ |
16 | 7.32 (d, J = 8.9 Hz, 1H), 7.18 (d, J = 10.3 Hz, 4H), 6.78 (d, J = 8.9 Hz, 1H), 6.71 (s, 0H), 4.28 (s, 1H), 3.59 (s, 9H), 3.53 (s, 1H), 3.08 (s, 1H), 3.01 (s, 1H), 2.74 (t, J = 6.5 Hz, 1H), 2.56 (s, 1H), 2.23 (s, 1H), 2.01 (s, 3H), 1.92 (s, 2H) | 457.0[M+H]+ |
17 | 7.31 (t, J = 9.2 Hz, 3H), 7.15 (d, J = 8.1 Hz, 2H), 6.76 (d, J = 9.0 Hz, 1H), 6.70 (s, 1H), 4.21 (s, 2H), 3.63 – 3.42 (m, 6H), 3.06 (s, 4H), 3.00 (s, 2H), 2.72 (t, J = 6.6 Hz, 2H), 2.56 (s, 3H), 2.00 (s, 6H), 1.94 – 1.81 (m, 2H), 1.22 (s, 9H) | 499.3[M+H]+ |
18 | 7.72 – 7.58 (m, 4H), 7.46 (t, J = 7.5 Hz, 2H), 7.36 (t, J = 7.7 Hz, 4H), 6.81 (d, J = 8.9 Hz, 1H), 6.74 (s, 1H), 4.35 (s, 2H), 3.70 – 3.59 (m, 6H), 3.56 (d, J = 4.0 Hz, 4H), 3.07 (d, J = 25.2 Hz, 4H), 2.77 (t, J = 6.5 Hz, 2H), 2.65 (s, 3H), 2.04 (s, 3H), 1.99 – 1.77 (m, 2H) | 519.3[M+H]+ |
19 | 7.33 – 7.19 (m, 6H), 6.76 (d, J = 9.7 Hz, 1H), 6.73 (s, 1H), 3.57 (s, 6H), 3.50 (d, J = 5.3 Hz, 2H), 3.10 (s, 2H), 3.03 (s, 2H), 2.80 (d, J = 8.0 Hz, 2H), 2.77 (s, 3H), 2.74 (d, J = 6.6 Hz, 2H), 2.05 (s, 3H), 1.89 (d, J = 4.9 Hz, 2H) | 457.3[M+H]+ |
20 | 7.85 (d, J = 8.0 Hz, 2H), 7.49 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 8.9 Hz, 1H), 6.81 (d, J = 9.0 Hz, 1H), 6.75 (s, 1H), 4.43 (s, 2H), 3.66 – 3.54 (m, 7H), 3.12 (s, 4H), 3.06 (s, 2H), 2.78 (t, J = 6.5 Hz, 2H), 2.67 (s, 3H), 2.06 (s, 3H), 2.00 – 1.87 (m, 2H). | 471.3[M+H]+ |
21 | 7.36 (dt, J = 12.6, 8.9 Hz, 5H), 6.80 (d, J = 9.1 Hz, 1H), 6.74 (s, 1H), 4.34 (s, 2H), 3.66 – 3.46 (m, 6H), 3.10 (s, 2H), 3.04 (s, 2H), 2.76 (t, J = 6.6 Hz, 2H), 2.63 (s, 3H), 2.04 (s, 3H), 1.94 (dd, J = 12.0, 6.2 Hz, 2H) | 527.2[M+H]+ |
22 | 7.85 (d, J = 8.0 Hz, 2H), 7.49 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 8.9 Hz, 1H), 6.81 (d, J = 9.0 Hz, 1H), 6.75 (s, 1H), 4.43 (s, 2H), 3.66 – 3.54 (m, 7H), 3.12 (s, 4H), 3.06 (s, 2H), 2.78 (t, J = 6.5 Hz, 2H), 2.67 (s, 3H), 2.06 (s, 3H), 2.00 – 1.87 (m, 2H). | 468.3[M+H]+ |
23 | 7.38 – 7.18 (m, 6H), 6.79 (d, J = 9.1 Hz, 1H), 6.72 (s, 1H), 4.26 (s, 2H), 3.63 – 3.51 (m, 2H), 3.18 (d, J = 9.0 Hz, 8H), 2.89 (s, 3H), 2.73 (t, J = 6.6 Hz, 2H), 2.57 (s, 3H), 1.91 (dd, J = 11.9, 6.1 Hz, 2H). | 479.0[M+H]+ |
24 | 7.32 (t, J = 9.2 Hz, 3H), 7.16 (d, J = 8.2 Hz, 2H), 6.79 (dd, J = 9.1, 2.6 Hz, 1H), 6.72 (d, J = 2.3 Hz, 1H), 4.22 (s, 2H), 3.62 – 3.51 (m, 2H), 3.18 (dd, J = 13.6, 5.2 Hz, 8H), 2.89 (s, 3H), 2.73 (t, J = 6.6 Hz, 2H), 2.56 (s,2H), 2.00 – 1.84 (m, 2H), 1.23 (s, 9H). | 535.0[M+H]+ |
25 | 7.26 (t, J = 9.2 Hz, 3H), 7.10 (d, J = 8.2 Hz, 2H), 6.73 (dd, J = 9.1, 2.6 Hz, 1H), 6.66 (d, J = 2.3 Hz, 1H), 4.16 (s, 2H), 3.58 – 3.44 (m, 2H), 3.13 (d, J = 5.1 Hz, 5H), 3.10 (d, J =5.4 Hz, 4H), 2.83 (s, 3H), 2.67 (t, J = 6.6 Hz, 2H), 2.50 (s, 3H), 1.85 (dd, J = 11.9, 6.1 Hz, 2H), 1.17 (s, 9H) | 549.0[M+H]+ |
26 | 7.31 (dd, J = 11.7, 8.7 Hz, 3H), 7.15 (d, J = 8.1 Hz, 2H), 6.75 (dd, J = 9.0, 2.4 Hz, 1H), 6.67 (s, 1H), 4.20 (s, 2H), 3.74 – 3.62 (m, 4H), 3.62 – 3.50 (m, 2H), 3.06 – 2.95 (m, 4H), 2.72 (t, J = 6.6 Hz, 2H), 2.55 (s, 3H), 2.08 – 1.71 (m, 2H), 1.22 (s, 9H) | 458.0[M+H]+ |
27 | 8.72 (s, 1H), 7.80 (d, J = 8.6 Hz, 2H), 7.44 (d, J = 8.7 Hz,1H), 7.38 (d, J = 8.0 Hz, 2H), 7.21 (d, J = 8.0 Hz, 2H), 7.09 – 6.94 (m, 4H), 4.29 (s, 2H), 3.79 (s, 3H), 3.67 (s,2H), 2.80(t, J = 6.2 Hz, 2H), 2.64 (s, 3H), 1.97 (s, 2H), 1.27 (s, 9H). | 522.0[M+H]+ |
28 | 8.63 (s, 0H), 7.78 (d, J = 8.0 Hz, 1H), 7.42 (d, J = 8.7 Hz, 1H), 7.36 (d, J = 7.6 Hz, 2H), 7.20 (d, J = 7.7 Hz, 1H), 7.12 – 6.92 (m, 2H), 4.28 (s, 1H), 3.65 (s, 1H), 3.18 (s, 0H), 2.79 (t, J= 6.0 Hz, 2H), 2.63 (s, 1H), 1.96 (s, 2H), 1.26 (s, 9H) | 508.0[M+H]+ |
29 | 8.72 (s, 1H), 7.73 (d, J = 8.6 Hz, 1H), 7.44 (d, J = 8.8 Hz, 1H), 7.37 (d, J = 8.0 Hz, 2H), 7.20 (d, J = 8.0 Hz, 2H), 7.08 – 6.94 (m, 2H), 6.88 (d, J = 8.8 Hz, 1H), 6.81 (s, 1H), 4.28 (s,2H), 3.72 – 3.60 (m, 2H), 2.81 (d, J = 6.5 Hz, 4H), 2.63 (s, 3H), 2.47 (s, 2H), 1.96 (d, J = 5.1 Hz, 4H), 1.26 (s, 9H). | 532.3[M+H]+ |
30 | 7.36 (d, J = 8.1 Hz, 2H), 7.31 (d, J = 9.0 Hz, 1H), 7.18 (d, J = 8.1 Hz, 2H), 6.77 (d, J = 9.1 Hz, 1H), 6.71 (s, 1H), 4.24 (s, 2H), 3.62 (s, 3H), 3.61 – 3.52 (m, 4H), 2.82 – 2.64 (m, 4H), 2.59 (s, 3H), 2.48 (d, J = 14.6 Hz, 1H), 1.99 – 1.82 (m, 4H), 1.67 (t, J = 10.6 Hz, 2H), 1.26 (s, 9H). | 514.0[M+H]+ |
31 | 12.27 (s, 1H), 7.36 (d, J = 8.2 Hz, 2H), 7.32 (s, 1H), 7.19 (d, J = 8.1 Hz, 2H), 6.81 (s, 2H), 4.24 (s, 2H), 3.59 (dd, J = 16.2, 10.4 Hz, 4H), 2.75 (t, J = 6.5 Hz, 4H), 2.61 (d, J = 16.0 Hz, 3H), 2.39 (s, 1H), 2.00 – 1.81 (m, 4H), 1.68 (s, 2H), 1.26 (s, 9H). | 500.0[M+H]+ |
32 | 7.91 (d, J = 7.7 Hz, 1H), 7.45 (d, J = 8.2 Hz, 2H), 7.38 (d, J = 9.0 Hz, 1H), 7.28 (d, J = 8.2 Hz, 2H), 6.86 (dd, J = 9.1, 2.5 Hz, 1H), 6.80 (s, 1H), 4.33 (s, 2H), 3.76 (d, J = 7.2 Hz, 1H), 3.68 (dd, J = 11.1, 4.8 Hz, 4H), 2.83 (d, J = 7.1 Hz, 4H), 2.68 (s, 3H), 2.06 – 1.98 (m, 2H), 1.88 (s, 5H), 1.54 (dd, J = 20.4, 11.3 Hz, 3H), 1.36 (s, 9H), 1.32 (s, 3H). | 513.1[M+H]+ |
33 | 8.63 (s, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.42 (d, J = 8.7 Hz, 1H), 7.36 (d, J = 7.6 Hz, 2H), 7.20 (d, J = 7.7 Hz, 1H), 7.12 – 6.92 (m, 2H), 4.28 (s, 1H), 3.65 (s, 1H), 3.18 (s, 0H), 2.79 (t, J= 6.0 Hz, 2H), 2.63 (s, 1H), 1.96 (s, 2H), 1.26 (s, 9H) | 508.0[M+H]+ |
34 | 7.36 (d, J = 8.2 Hz, 2H), 7.32 (s, 1H), 7.19 (d, J = 8.1 Hz, 2H), 6.81 (s, 2H), 4.24 (s, 2H), 3.59 (dd, J = 16.2, 10.4 Hz, 4H), 2.75 (t, J = 6.5 Hz, 4H), 2.61 (d, J = 16.0 Hz, 3H), 2.39 (s, 1H), 2.00 – 1.81 (m, 4H), 1.68 (s, 2H), 1.26 (s, 9H). | 500.0[M+H]+ |
35 | 7.46 – 7.24 (m, 5H), 7.19 (d, J = 8.1 Hz, 2H), 4.28 (s,2H), 3.71 – 3.61 (m, 2H), 2.79 (t, J = 6.5 Hz, 2H), 1.96 – 1.75 (m, 2H), 1.27 (s, 9H). | 437.2[M+H]+ |
36 | 7.48 – 7.24 (m, 5H), 7.18 (d, J = 8.1 Hz, 2H), 4.30 (s,2H), 3.73 – 3.61 (m, 2H), 2.79 (t, J = 6.5 Hz, 2H), 1.99 – 1.76 (m, 2H), 1.29 (s, 9H). | 437.2[M+H]+ |
37 | 7.46 – 7.24 (m, 5H), 7.19 (d, J = 8.1 Hz, 2H), 4.28 (s,2H), 3.71 – 3.61 (m, 2H), 2.79 (t, J = 6.5 Hz, 2H), 1.96 – 1.75 (m, 2H), 1.27 (s, 9H). | 437.1[M+H]+ |
Embodiment 33:
Pharmacological activity:
Activity test in vitro:The present invention is using double fluorescence resonance energy transfer (fluorescence resonance energy
Transfer, FRET) method validation the compounds of this invention inhibition RORgt protein actives ability.
Test compound is dissolved in dimethyl sulfoxide (DMSO) to prepare 10.0mM stock solutions and be diluted to required dense
Degree.DMSO ultimate densities in reaction are no more than 1% (v/v).By in the chemical combination presence or absence of required concentration
In the case of object by GST label ROR γ ligand binding domains (LBD) be mixed in containing 25mM HEPES, 100mM NaCl,
In the buffer of 5mM DTT and 0 .01%BSA, incubated 1 hour at 25 DEG C.By Steroid Receptor
Coactivator-1 (SRC-1), (676-700), biotin labeled and MAb Anti GST-Tb and
Streptavidin-d2 is added to reaction mixture and shakes again after five minutes, by reactant again at room temperature incubate 1 hour and
At 4 DEG C in SpectraMax Paradigm microplate reader read 620,665 signal, according to 620/665 TR-FRET ratios
Rate tests the inhibitory activity of compound to calculate.By using the nonlinear regression analysis of GraphPad Prism softwares, according to
Compound concentration suppression curve calculates IC50 values.
Prepared compound is tested using said determination program and acquired results are provided in table 3.It measures described
Compound has the IC50 less than 5 μM, preferably smaller than 1 μM, more preferably less than 0.1 μM.
IC50 (μM) value is set forth in table 1, wherein " A " refers to the IC50 values less than 0.1 μM, " B " refers to being more than 0.1 μM
And it is less than the IC50 values within the scope of 1 μM, " C " refers to being less than the IC50 values within the scope of 5 μM more than 1 μM, and " D " refers to being more than 5 μM
IC50 values, " NA " refers to not detecting.
The FRET activity datas of 3. compound of table
Compound | IC50 | Compound | IC50 |
1 | B | 20 | D |
2 | D | 21 | C |
3 | C | 22 | D |
4 | B | 23 | D |
5 | C | 24 | B |
6 | B | 25 | B |
7 | C | 26 | B |
8 | D | 27 | B |
9 | B | 28 | C |
10 | D | 29 | A |
11 | C | 30 | NA |
12 | B | 31 | NA |
13 | B | 32 | NA |
14 | B | 33 | NA |
15 | C | 34 | NA |
16 | B | 35 | NA |
17 | B | 36 | NA |
18 | C | 37 | NA |
19 | B |
As known from Table 3, the compound of the present invention has inhibitory activity to ROR γ t, this is that exploitation is efficient, novel, high specificity
ROR γ the t inflammation, tumour and the autoimmune disease that mediate such as cancer, psoriasis, rheumatoid arthritis, multiple hard
The drug of the inflammation such as change and autoimmune disease is laid a good foundation, and has good Development volue.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
Member, under the premise of not departing from the present invention, can also make several improvement and supplement, these are improved and supplement also should be regarded as this hair
Bright protection domain.
Claims (10)
1. compound of formula I
(I)
Wherein:
X1 is C or N;
X2 is halogen, NH or O;
M is optionally from 0,1;
N is optionally from 0,1,2 or 3;
Substituent R 1 is selected from:H, (C1- C3) alkyl, halogen (C1- C3) alkyl, aryl, heteroaryl, heterocycle and naphthenic base;
Substituent R 2 is not present or is located at least one of 2,3,4,5,6 positions, is unsubstituted, mono-substituted, double take
It is generation or polysubstituted, the one kind in following groups of substituent R 2, two or more:Hydrogen, halogen, nitro, hydroxyl, carboxylic
Base, trifluoromethyl, cyano, substituted or unsubstituted amino, phenyl, substituted or unsubstituted (C1-C6) alkyl, substitution do not take
(C1-C6) alkoxy in generation ,-CONH2、-CONHR3、 -CON(R3)2、 -COOR3、 -COR3、 -NHCOR3、 -NHCOOR3
Group, wherein R3 are optionally from H, (C1-C6) alkyl, trifluoromethyl, phenyl;When R2 is double or three substitution, substituent group it is identical or
It is different;
Cy1 be not present or optionally from:H, Ar1, Hetar1 or (C3-C7) naphthenic base
Above Ar1 indicates to have the monocyclic aromatic hydrocarbon system of 6-10 carbon atom or bicyclic aromatic hydrocarbon system and aromatic hydrocarbon to be saturated simultaneously
Member ring systems, the system is unsubstituted or is replaced by one or more identical or different substituent groups selected from the following:(C1-C6)-
Alkyl, (C1-C6)-alkoxy, (C3-C7)-naphthenic base, carbonyl, carboxyl, amino ,-CONH2、-COOR4、-COR4、-
NHCOR4、-NHCOOR4、-COH(CF3)2,-SONH2 ,-SOOR4 ,-SOR4 ,-NHSOR4 ,-NHSOOR4 groups substitution;Wherein
R4 is optionally from H, (C1-C6) alkyl;
The above Hetar1 indicates saturation 4,5,6,7,8,9 or 10 circle heterocyclic rings with 1,2 or 3 N and/or O and/or S atom, should
Heterocycle is unsubstituted or is replaced by one or more identical or different substituent groups selected from the following:(C1-C6)-alkyl, (C1-
C6)-alkoxy, (C3-C7)-naphthenic base, carbonyl, carboxyl, amino ,-CONH2、-COOR4、-COR4、-NHCOR4、-
NHCOOR4、-COH(CF3)2,-SONH2 ,-SOOR4 ,-SOR4 ,-NHSOR4 ,-NHSOOR4 groups substitution;Wherein R4 is optionally certainly
H, (C1-C6) alkyl.
2. compound according to claim 1, which is characterized in that the substituent R 1 occurs being methyl every time.
3. compound according to claim 1 or claim 2, which is characterized in that the substituent R 2 is located in 2,3,4,5,6 extremely
A few position, is unsubstituted, mono-substituted, disubstituted or polysubstituted, the substituent R 2 is in following groups
One kind, two or more:Hydrogen, fluorine, chlorine, trifluoromethyl, cyano, methyl, phenyl, trifluoromethoxy, tertiary butyl, when R2 is double
Or when three substitutions, substituent group is identical or different.
4. according to the compound of claims 1 to 3, which is characterized in that the X2 is selected from bromine or N.
5. according to any one of claims 1 to 4 compound, which is characterized in that the Cy1 is optionally certainly:1- acetyl group
Piperazinyl, 1- (propiono)-piperazinyl, 1- cyclopropane carbonyls piperazinyl, 1- pivaloyl groups piperazinyl, 1- pivaloyls
Base piperazinyl, 1- mesylpiperazinyls, 1- piperazines sulfoamido, 1- ethylsulfonyls piperazinyl, morpholinyl, piperazinyl, benzene first
Sour carbomethoxy, benzoxy, naphthalene, tetralyl, 3,4- dihydros -1 (2H)-naphthalenone base, piperidyl, 4- piperidine methyl formates
Base, 4- piperidinecarboxylic acids base, 4- acetamido piperidyls.
6. claim 1-5 any one of them 1,2,3,4- tetrahydroquinoline sulfonic acid amide derivatives is pharmaceutically acceptable
Salt, solvate, precursor compound or polymorph.
7. the pharmaceutically acceptable salt, solvate, precursor compound according to claims 1-6 or polymorph,
It is characterized in that, the pharmaceutically acceptable salt is inorganic salts, organic salt or amino-acid salt;
Wherein inorganic salts are:Sodium salt, hydrochloride, sulfate, phosphate, diphosphate, hydrobromate or nitrate;
Wherein organic salt is:Acetate, maleate, fumarate, tartrate, succinate, lactate, p-methyl benzenesulfonic acid
Salt, salicylate or oxalates;
Wherein amino-acid salt is:Arginine salt, ornithine salt, lysine salt, leucine salt, isoleucine salt, glycinate, Guang
Propylhomoserin salt, cysteine salt, tyrosine salt, alanine salt, phenylalanine salt, histidine salt, serine salt, threonine salt, egg
Propylhomoserin salt, tryptophan salt, glutamate, aspartate, valine salt, methionine salt, proline salt or hydroxyproline salt.
8. a kind of pharmaceutical composition, which is characterized in that it includes a)Any 1,2,3,4- tetrahydroquinolines sulphurs of claim 1-5
The pharmaceutically acceptable salt of 1,2,3,4- tetrahydroquinoline sulfonic acid amide derivatives described in amide derivatives, claim 6,
The one or more and b of solvate, precursor compound and polymorph)Its pharmaceutically acceptable carrier.
9. any 1,2,3, the 4- tetrahydroquinoline sulfonic acid amide derivatives of claim 1-5,1,2 described in claim 6,
Pharmaceutically acceptable salt, its solvate, pro-drug or the polymorph of 3,4- tetrahydroquinoline sulfonic acid amide derivatives, or
Pharmaceutical composition according to any one of claims 8 is being prepared for treating in inflammation, autoimmune disease, diabetes, cancer at least
A kind of purposes in the drug of disease.
10. purposes as described in claim 9, which is characterized in that the disease is:It is diabetes, encephalomyelitis, multiple hard
Change disease, rheumatic arthritis, Collagen-induced Arthritis, psoriasis, inflammatory bowel disease, clone's disease, asthma, lung's disease
At least one of disease, chronic obstructive pulmonary disease (COPD), asthma, colitis and ulcerative colitis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710106749.8A CN108503584B (en) | 2017-02-27 | 2017-02-27 | 1,2,3, 4-tetrahydroquinoline sulfonamide compound and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710106749.8A CN108503584B (en) | 2017-02-27 | 2017-02-27 | 1,2,3, 4-tetrahydroquinoline sulfonamide compound and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108503584A true CN108503584A (en) | 2018-09-07 |
CN108503584B CN108503584B (en) | 2021-05-04 |
Family
ID=63373053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710106749.8A Active CN108503584B (en) | 2017-02-27 | 2017-02-27 | 1,2,3, 4-tetrahydroquinoline sulfonamide compound and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108503584B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109568321A (en) * | 2019-01-14 | 2019-04-05 | 山东轩竹医药科技有限公司 | ROR gamma modulators |
CN112830893A (en) * | 2019-10-28 | 2021-05-25 | 成都倍特药业股份有限公司 | ROR gamma inhibitor, preparation method and medical application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012064744A2 (en) * | 2010-11-08 | 2012-05-18 | Lycera Corporation | Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease |
CN104284657A (en) * | 2012-05-08 | 2015-01-14 | 默沙东公司 | Bicyclic sulfone compounds for inhibition of RORgamma activity and the treatment of disease |
CN106458991A (en) * | 2014-05-23 | 2017-02-22 | 豪夫迈·罗氏有限公司 | Benzene sulfonamide derivatives and their use as RORC modulators |
-
2017
- 2017-02-27 CN CN201710106749.8A patent/CN108503584B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012064744A2 (en) * | 2010-11-08 | 2012-05-18 | Lycera Corporation | Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease |
CN104284657A (en) * | 2012-05-08 | 2015-01-14 | 默沙东公司 | Bicyclic sulfone compounds for inhibition of RORgamma activity and the treatment of disease |
CN106458991A (en) * | 2014-05-23 | 2017-02-22 | 豪夫迈·罗氏有限公司 | Benzene sulfonamide derivatives and their use as RORC modulators |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109568321A (en) * | 2019-01-14 | 2019-04-05 | 山东轩竹医药科技有限公司 | ROR gamma modulators |
CN112830893A (en) * | 2019-10-28 | 2021-05-25 | 成都倍特药业股份有限公司 | ROR gamma inhibitor, preparation method and medical application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN108503584B (en) | 2021-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2011245248B2 (en) | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites | |
JP5992615B2 (en) | Aromatic compounds substituted with cyclopropanecarboxamide, an anticancer drug | |
EP1866286B1 (en) | Pyridine derivatives useful as inhibitors of pkc-theta | |
KR101047274B1 (en) | Cyclohexyl Sulfonamide Derivatives Having H3 Receptor Activity | |
CN104352492A (en) | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient | |
SG177289A1 (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
WO2013134298A1 (en) | Raf inhibitor compounds | |
KR20090064480A (en) | Phenylurea compounds as soluble epoxide hydrolase inhibitors | |
CA2985769C (en) | Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same | |
EP3080125A1 (en) | Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same | |
US10689361B2 (en) | Quinoline derivative and use thereof | |
BR112014002958B1 (en) | 3,4-DIHIDRO-1H- [1,8] NAPHYDRIDINES SUBSTITUTED WITH PIPERIDINYLES ANTIBACTERIALS, PHARMACEUTICAL COMPOSITION UNDERSTANDING THOSE COMPOUNDS, PROCESSES FOR THE PREPARATION OF THESE AND USE | |
BR112019025836A2 (en) | aminopyrimidine compound, method of preparing it and using it | |
CA2824536A1 (en) | Protease activated receptor 2 (par2) antagonists | |
PT2238110E (en) | 5.6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as antagonists for urotensine ii receptors | |
BR112014003146A2 (en) | 3,4-DIHIDRO-1H- [1,8] NAPHYDRIDINES REPLACED WITH ANTIBACTERIAL HOMOPIPERIDINYL, PHARMACEUTICAL COMPOSITION UNDERSTANDING THOSE COMPOUNDS, PROCESSES FOR5 PREPARATION OF THESE AND USE | |
EP4121167A1 (en) | Selective modulators of mutant lrrk2 proteolysis and associated methods of use | |
CA2977837A1 (en) | Ghrelin o-acyl transferase inhibitors | |
CN111094265A (en) | Pyrazole derivative compound and use thereof | |
CN107286130A (en) | A kind of Kinase Selectivity inhibitor | |
CN106928200A (en) | For the pyrrolotriazine derivatives for the treatment of cancer | |
CN108503584A (en) | A kind of 1,2,3,4- tetrahydroquinolines sulfamide compound and its application | |
CN103965195B (en) | Compound and application thereof for discoidin domain receptor micromolecular inhibitor | |
JP2011519966A (en) | Novel N- (2-amino-phenyl) -acrylamide | |
US20100069443A1 (en) | Compound with benzamide skeleton having cyclooxygenase-1 (cox-1)-selective inhibitory activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |